¡à ÁÖÁ¦: ±Û·Î¹ú Ç×¾Ï½Å¾à °³¹ß±¹°¡·ÎÀÇ µµ¾à
(From Discovery to Cancer Therapeutics)
¡à ÀϽÃ: 2009. 6. 19(±Ý) 09:00-16:30
¡à Àå¼Ò: ±¹¸³¾Ï¼¾ÅÍ ±¹°¡¾Ï¿¹¹æ°ËÁøµ¿ 8Ãþ ±¹Á¦È¸ÀÇÀå/ ÃæºÏÀÇ´ë È»óȸÀǽÇ(½Å°ü 4Ãþ; 043-261-3460)
±¹¹ÎÀ» ¾ÏÀ¸·ÎºÎÅÍ º¸È£Çϱâ À§ÇØ ¼³¸³µÈ ±¹¸³¾Ï¼¾ÅÍ´Â ¾Ï ºÐ¾ßÀÇ Çö¾È¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ Åä·ÐÀ» ÅëÇØ ¿ì¸®³ª¶óÀÇ ¾Ï ¿¬±¸, Áø·á ¹× ±¹°¡¾Ï°ü¸® ¼öÁØ Çâ»ó¿¡ ±â¿©Çϱâ À§ÇØ 2007³âµµºÎÅÍ ±¹Á¦ ½ÉÆ÷Áö¾öÀ» °³ÃÖÇÏ°í ÀÖ½À´Ï´Ù. ¿ÃÇØ¿¡´Â ¡®±Û·Î¹ú Ç×¾Ï½Å¾à °³¹ß±¹°¡·ÎÀÇ µµ¾à¡¯À̶õ ÁÖÁ¦·Î Á¦3ȸ ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦ ½ÉÆ÷Áö¾öÀ» °³ÃÖÇÕ´Ï´Ù.
º» ½ÉÆ÷Áö¾ö¿¡¼´Â ±Û¸®º¤, ¼öÅÙÆ® µî ºí·Ï¹ö½ºÅÍ Çõ½Å Ç×¾ÏÁ¦¸¦ °³¹ßÇÑ ¼¼°èÀûÀÎ Ç×¾ÏÁ¦ °³¹ß Àü¹®°¡¸¦ ¸ð½Å °¡¿îµ¥ Ç×¾Ï ½Å¾à °³¹ß µ¿Çâ ¹× ±Û·Î¹ú Ç×¾Ï½Å¾à °³¹ß »ç·Ê¿Í Àå¾Ö ¿äÀÎ µîÀ» ÆľÇÇÏ°í, ÇФý¿¬¤ý»ê ¹× Á¤ºÎ µî ½Å¾à °³¹ß °ü·Ã ÁÖüµéÀÇ ¿ªÇÒ ¹× Çù·Â ¹æ¾ÈÀ» µµÃâÇÏ°íÀÚ ÇÕ´Ï´Ù.
º» Çà»ç°¡ ¿ì¸®³ª¶óÀÇ ±Û·Î¹ú Ç×¾Ï½Å¾à °³¹ß¿¡ ±â¿©ÇÒ ¼ö ÀÖ´Â À¯ÀÍÇÑ Åä·ÐÀÇ ÀåÀÌ µÉ ¼ö ÀÖµµ·Ï Àû±Ø Âü¼®ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
±¹¸³¾Ï¼¾ÅÍ¿øÀå ÀÌÁø¼ö
¡à ÇÁ·Î±×·¥
09:00-9:30 |
Registration |
09:30-9:50 |
Opening |
Session I |
Lessons of the Past for Future Success |
09:50-10:30 |
Paving a New Road to Cure Cancer
- Prof. Sunghoon Kim (Professor, Seoul Natl Univ., Korea) |
Chairs :
Dr. Seung-Hoon Lee (NCC),
Prof. Sunghoon Kim (SNU) |
10:30-11:10 |
Cancer Drug Discovery in the 21stCentury
- Dr. Alex Matter (CEO, Experimental Therapeutics Centre, A*STAR,Singapore; CEO, Esperanza Medicines Foundation, Switzerland) |
11:10-11:20 |
Break |
11:20-12:00 |
Rational Development of Sunitinib Malate (SUTENT¢ç)
- Dr. Darrel Cohen (Senior Director, Pfizer, U.S.A.) |
Chairs :
Prof. Jae-Kyung Roh (Yonsei Univ.),
Prof. Young-Joon Surh (SNU) |
12:00-12:40 |
Role of Inflammation in Metastatic Progression: From Basic Research to Potential Therapeutics
- Prof. Michael Karin (Distinguished Professor, UCSD Cancer Center, U.S.A.) |
12:40-13:30 |
Lunch |
Session II |
Future of Anticancer Drugs : Novel Targets & Therapeutics |
13:30-14:10 |
Structural Chemoproteomics-based Novel Cancer Drug Discovery for Molecular Target Therapy
- Dr. Joong Myung Cho (CEO, Crystal Genomics Inc., Korea) |
Chairs :
Prof. Young-Ger Suh (SNU),
Dr. Young-Woo Park (KRIBB) |
14:10-14:50 |
Using Stratified Medicine and Biomarkers to Re-Accelerate Cancer Drug Development
- Dr. Eric Rowinsky (Chief Medical Officer & Executive Vice-President, Imclone Systems; Adjunct Professor of Medicine, NY Univ., U.S.A.) |
14:50-15:00 |
Break |
15:00-15:40 |
Funding for Biotechnology Start-up
- Dr. Thomas Neenan (CEO, Warwick Effect Polymers, U.K.) |
Chairs :
Dr. Young-Whan Park (Daewoong Pharma.),
Prof. Dae-Seog Heo (SNU) |
15:40-16:20 |
Bridging & Development for Cancer Therapeutics in Korea
- Dr. Jin-Soo Lee (President, National Cancer Center, Korea) |
16:20-16:30 |
Closing |
¡à °ü·Ã ¹®ÀÇ: ±³À°ÈÆ·ÃÆÀ ÃÖÁ¤Èñ | TEL. 031 920 0808 | FAX. 031 920 1959 | EML. symposium@ncc.re.kr